Posted in pre-market 
July 8th, 2009

Amgen Inc. (Nasdaq: AMGN) shares are up about 13 percent to around $59 on volume of 16,000 shares in very early premarket trading on Wednesday.

After the close, the company announced positive Phase III trial results of its osteoporosis drug Denosumab. The clinical results were strong enough to possibly make the drug the standard of care to treat patients with metastasized breast cancer, replacing Novartis Inc.’s (NYSE: NVS) Zometa.

Get the complete details at

Comments are closed